Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Nov 20;371(21):1994-2004.
doi: 10.1056/NEJMoa1407309.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B

Amit C Nathwani  1 , Ulreke M Reiss, Edward G D Tuddenham, Cecilia Rosales, Pratima Chowdary, Jenny McIntosh, Marco Della Peruta, Elsa Lheriteau, Nishal Patel, Deepak Raj, Anne Riddell, Jun Pie, Savita Rangarajan, David Bevan, Michael Recht, Yu-Min Shen, Kathleen G Halka, Etiena Basner-Tschakarjan, Federico Mingozzi, Katherine A High, James Allay, Mark A Kay, Catherine Y C Ng, Junfang Zhou, Maria Cancio, Christopher L Morton, John T Gray, Deokumar Srivastava, Arthur W Nienhuis, Andrew M Davidoff
Affiliations
Clinical Trial

Long-term safety and efficacy of factor IX gene therapy in hemophilia B

Amit C Nathwani et al. N Engl J Med. .

Abstract

Background: In patients with severe hemophilia B, gene therapy that is mediated by a novel self-complementary adeno-associated virus serotype 8 (AAV8) vector has been shown to raise factor IX levels for periods of up to 16 months. We wanted to determine the durability of transgene expression, the vector dose-response relationship, and the level of persistent or late toxicity.

Methods: We evaluated the stability of transgene expression and long-term safety in 10 patients with severe hemophilia B: 6 patients who had been enrolled in an initial phase 1 dose-escalation trial, with 2 patients each receiving a low, intermediate, or high dose, and 4 additional patients who received the high dose (2×10(12) vector genomes per kilogram of body weight). The patients subsequently underwent extensive clinical and laboratory monitoring.

Results: A single intravenous infusion of vector in all 10 patients with severe hemophilia B resulted in a dose-dependent increase in circulating factor IX to a level that was 1 to 6% of the normal value over a median period of 3.2 years, with observation ongoing. In the high-dose group, a consistent increase in the factor IX level to a mean (±SD) of 5.1±1.7% was observed in all 6 patients, which resulted in a reduction of more than 90% in both bleeding episodes and the use of prophylactic factor IX concentrate. A transient increase in the mean alanine aminotransferase level to 86 IU per liter (range, 36 to 202) occurred between week 7 and week 10 in 4 of the 6 patients in the high-dose group but resolved over a median of 5 days (range, 2 to 35) after prednisolone treatment.

Conclusions: In 10 patients with severe hemophilia B, the infusion of a single dose of AAV8 vector resulted in long-term therapeutic factor IX expression associated with clinical improvement. With a follow-up period of up to 3 years, no late toxic effects from the therapy were reported. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00979238.).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Summary of Factor IX Activity and Liver Function after Vector Infusion in 10 Patients with Hemophilia B
The mean (±SD) levels of factor IX coagulation activity were determined at the indicated time points with the use of a one-stage clotting assay after the infusion of a low dose of vector (in Patients 1 and 2), an intermediate dose (in Patients 3 and 4), or a high dose (in Patients 5 through 10), as shown on the left y axis. The arrows at the top of the graphs show the time points for treatment with factor IX concentrate. The decline in plasma factor IX activity that was observed in some patients (i.e., Patients 1, 5, 6, 7, and 8) in the initial phase after gene transfer probably represents a washout of the factor IX concentrate from the circulation. Levels of serum alanine aminotransferase (ALT) over time are shown on the right y axis. The duration of treatment with prednisolone (P), starting at a dose of 60 mg per day that was followed by a gradual tapering of the dose, is shown in purple at the top of the graphs for Patients 5, 6, 7, and 10. The left y axis has been adjusted for the patients in the high-dose group to reflect higher factor IX levels in these patients. The x axis has been adjusted to show with greater detail the kinetics of elevations in ALT levels in these patients.
Figure 2
Figure 2. Effect of Gene Transfer on the Administration of Factor IX Concentrate and the Number of Bleeding Episodes before and after Gene Transfer
Shown are box plots comparing the year before gene transfer and the year after gene transfer with respect to the mean amount of factor IX concentrate that was administered (Panel A) and the number of bleeding episodes (Panel B) in the 10 study patients. The top and bottom of each box represent the interquartile range, the horizontal line within the box represents the median (with the absence of a horizontal line indicating a median >10 times the 99th percentile), and the I bars represent the minimum and maximum values.
See this image and copyright information in PMC

Comment in

Similar articles

  • Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
    Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, Dolan G, Reiss U, Phillips M, Riddell A, Peralta MR, Quaye M, Patch DW, Tuddenham E, Dane A, Watissée M, Long A, Nathwani A. Chowdary P, et al. N Engl J Med. 2022 Jul 21;387(3):237-247. doi: 10.1056/NEJMoa2119913. N Engl J Med. 2022. PMID: 35857660 Clinical Trial.
  • Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. George LA, et al. N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi: 10.1056/NEJMoa1708538. N Engl J Med. 2017. PMID: 29211678 Free PMC article. Clinical Trial.
  • Gene therapy for hemophilia: advancing beyond the first clinical success.
    Monahan PE, Gui T. Monahan PE, et al. Curr Opin Hematol. 2013 Sep;20(5):410-6. doi: 10.1097/MOH.0b013e328363c1a1. Curr Opin Hematol. 2013. PMID: 23852185 Review.
  • Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
    Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. Nathwani AC, et al. N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoa1108046. Epub 2011 Dec 10. N Engl J Med. 2011. PMID: 22149959 Free PMC article. Clinical Trial.
  • AAV-mediated gene transfer for hemophilia.
    High KA. High KA. Ann N Y Acad Sci. 2001 Dec;953:64-74. doi: 10.1111/j.1749-6632.2001.tb11361.x. Ann N Y Acad Sci. 2001. PMID: 11795424 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nathwani AC, Tuddenham EG. Epidemiology of coagulation disorders. Baillieres Clin Haematol. 1992;5:383–439. - PubMed
    1. Ponder KP, Srivastava A. Walk a mile in the moccasins of people with haemophilia. Haemophilia. 2008;14:618–620. - PubMed
    1. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol. 2012;87(Suppl 1):S33–S39. - PubMed
    1. Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A. 1997;94:5804–5809. - PMC - PubMed
    1. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56–63. - PubMed

Publication types

Associated data

-